On September 8, Stryker fell 7.68% in regular trading, trading at $279.29/share, with turnover of $5.56 billion. The stock hit its lowest level since November 2023.

On the news front, Stryker CFO Preston Wells and VP of Investor Relations Nick Mead participated in a fireside chat at the Wells Fargo Healthcare Conference held at the Encore Boston Harbor. The event coincided with broad-based selling across the healthcare equipment sector. Boston Scientific fell 4.62%, Intuitive Surgical dropped 4.67%, Medtronic declined 2.82%, and Abbott Laboratories lost 2.48%, with Stryker significantly leading the sector decline.

Notably, lingering investor concerns may have amplified the selloff. When Stryker reported Q2 results on July 30, adjusted EPS of $3.69 beat estimates by 5.73% and revenue of $6.59 billion topped expectations, yet the company simultaneously narrowed its full-year adjusted EPS guidance to $14.95-$15.10, effectively raising the low end while trimming the upper bound from a prior range of $14.90-$15.10. The stock fell 8% on that occasion. Piper Sandler subsequently lowered its price target to $390 from $420 while maintaining an Overweight rating.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)